Top

Published in:

01-01-2012 | Topic Review

Novel approaches to treating leptomeningeal metastases

Authors: Jai Grewal, Marlon Garzo Saria, Santosh Kesari

Published in: Journal of Neuro-Oncology | Issue 2/2012

Abstract

Leptomeningeal metastasis is a devastating complication of the central nervous system in patients with late-stage solid or hematological cancers. Leptomeningeal metastasis results from the multifocal seeding of the leptomeninges by malignant cancer cells. Although central nervous system metastasis usually presents in patients with widely disseminated and progressive late-stage cancer, malignant cells may spread to the cerebrospinal fluid during earlier disease stages in particularly aggressive cancers. Treatment of leptomeningeal metastasis is largely palliative but will often provide stabilization and protection from further neurological deterioration and improve quality of life. There is a need to raise awareness of the impact of leptomeningeal metastases on cancer patients and its known and putative biological basis. Novel diagnostic approaches include identification of biomarkers that may stratify the risk for developing leptomeningeal metastasis. Current therapies can be used more effectively while waiting for advanced treatments to be developed.

Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin N Am 21:25–66

Gleissner B, Chamberlain MC (2006) Neoplastic meningitis. Lancet Neurol 5:443–452PubMedCrossRef

Groves MD, Hess KR, Puduvalli VK et al (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 4:229–234CrossRef

Mitchell MS (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701–1709PubMed

O’Meara WP, Borkar SA, Stambuk HE et al (2007) Leptomeningeal metastasis. Curr Probl Cancer 31:372–424CrossRef

Theodore WH, Gendelman S (1981) Meningeal carcinomatosis. Arch Neurol 38:696–699PubMedCrossRef

Yap HY, Yap BS, Rasmussen S et al (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50:219–222PubMedCrossRef

Jorda M, Ganjei-Azar P, Nadji M (1998) Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 55:181–184PubMedCrossRef

Chamberlain MC (2006) CSF Disseminated primary brain tumors. In: Newton HB (ed) Handbook of brain tumor chemotherapy. Elsevier Science, San Diego, pp 316–326CrossRef

10.

Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14PubMedCrossRef

11.

Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375PubMed

12.

Gleissner B, Chamberlain MC (2007) Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 84:107–117PubMedCrossRef

13.

Hatton C (2005) Lymphomatous meningitis. Haematologica Rep 1:108–109

14.

Chamberlain MC (2008) Neoplastic meningitis. Curr Neurol Neurosci Rep 8:249–258PubMedCrossRef

15.

Yoshida S, Morii K, Watanabe M et al (2000) Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 53:163–167PubMedCrossRef

16.

Glantz MJ, Cole BF, Glantz LK et al (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733–739PubMedCrossRef

17.

Ward MS (1999) The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. Pathology 31:382–392PubMedCrossRef

18.

Johanson CE, Duncan JA, Stopa EG et al (2005) Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011–1037PubMedCrossRef

19.

Kobayashi Z, Tsuchiya K, Machida A et al (2009) Metastatic CNS lymphoma presenting with periventricular dissemination–MRI and neuropathological finding in an autopsy case. J Neurological Sci 277:109–113CrossRef

20.

Levine S (1987) Choroid plexus: target for systemic disease and pathway to the brain. Lab Invest 56:231–233PubMed

21.

Oldstone MB, Southern PJ (1993) Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. J Neuroimmunol 46:25–31PubMedCrossRef

22.

Groves MD (2003) The pathogenesis of neoplastic meningitis. Curr Oncol Rep 5:15–23PubMedCrossRef

23.

Alix-Panabieres C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14:5013–5021PubMedCrossRef

24.

Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813–2820PubMedCrossRef

25.

Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679PubMedCrossRef

26.

Fidler IJ, Langley RR, Kerbel RS et al (2005) Angiogenesis. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology. Lippincott Williams & Wilkins, New York, pp 129–135

27.

Kraft A, Weindel K, Ochs A et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178–187PubMedCrossRef

28.

Stockhammer G, Poewe W, Burgstaller S et al (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54:1670–1676PubMed

29.

Goswami S, Phillippar U, Sun D et al (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26:153–159PubMedCrossRef

30.

Kadoch C, Treseler P, Rubenstein JL (2006) Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 21:E1PubMedCrossRef

31.

Lee B-C, Lee T-H, Avraham S et al (2004) Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2:327–338PubMed

32.

Singh S, Nannuru KC, Sandanandam A et al (2009) CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100:1638–1646PubMedCrossRef

33.

Philippar U, Roussos ET, Oser M et al (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15:813–828PubMedCrossRef

34.

Wyckoff J, Wang W, Lin EY et al (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029PubMedCrossRef

35.

Van Oostenbrugge RJ, Hopman AHN, Ramaekers FCS et al (1998) In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38:127–133PubMedCrossRef

36.

Van Oostenbrugge RJ, Hopman AHN, Arends JW et al (2000) Treatment of leptomeningeal metastasis evaluated by interphase cytogenetics. J Clin Oncol 18:2053–2058PubMed

37.

Baehring JM, Hochberg FH, Betensky RA et al (2006) Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 247:208–216PubMedCrossRef

38.

Gleissner B, Siehl J, Korfel A et al (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390–396PubMed

39.

Berg SL, Chamberlain MC (2003) Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5:29–40PubMedCrossRef

40.

Berg SL, Chamberlain MC (2005) Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 125:121–146PubMedCrossRef

41.

Chamberlain MC, Nolan C, Abrey LE (2005) Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75:71–83PubMedCrossRef

42.

Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694–699PubMedCrossRef

43.

Siegal T, Lossos A, Pfeffer MR (1994) Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44:1463–1469PubMed

44.

Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:2919–2931PubMedCrossRef

45.

Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75(12):2919–2931PubMedCrossRef

46.

Chamberlain MC, Glantz M (2006) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 66:783PubMedCrossRef

47.

Omuro AM, Lallana EC, Bilsky MH et al (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 10:1625–1627CrossRef

48.

Mocco J, Tomey MI, Komotar RJ et al (2006) Ventriculoperitoneal shunting of idiopathic normal pressure hydrocephalus increases midbrain size: a potential mechanism for gait improvement. Neurosurgery 59:847–851PubMedCrossRef

49.

Schiff D, Kline C, Meltzer H et al (2009) Palliative venticuloperitoneal shunt in a pediatric patient with recurrent metastatic medulloblastoma. J Palliat Med 12:391–393PubMedCrossRef

50.

Lokich J, Levine H, Nasser I (1998) Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients. Am J Clin Oncol 21:366–368PubMedCrossRef

51.

Eralp Y, Saip P, Aydin Z et al (2008) Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol 108:248–250PubMedCrossRef

52.

Matsumae M, Sato O, Itoh K et al (1989) Quantification of cerebrospinal fluid shunt flow rates. Assessment of the programmable pressure valve. Childs Nerv Syst 5:356–360PubMedCrossRef

53.

Chiafery M (2006) Care and management of the child with shunted hydrocephalus. Pediatr Nurs 32:222–225PubMed

54.

Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116PubMed

55.

Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safely of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892–1898PubMedCrossRef

56.

Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157PubMedCrossRef

57.

Cameron DA, Stein S (2008) Drug insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5:512–520PubMedCrossRef

58.

Lin NU, Diéras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459PubMedCrossRef

59.

Onishi H, Morisaki T, Nakafusa Y et al. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol. doi:10.1007/s10147-011-0195-5

60.

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef

61.

Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef

62.

Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400PubMedCrossRef

63.

Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344–2348PubMedCrossRef

64.

Jackman DM, Kesari S, Cioffredi L et al. (2009) Phase I study of high dose gefitinib in patients with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer. Presented at the 13th World Congress on Lung Cancer San Francisco, 31st July–4th August 2009; Poster P1.189

65.

Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80–84PubMedCrossRef

66.

Jackman DM, Holmes A, Lindeman N et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520PubMedCrossRef

67.

Clarke JL, Pao W, Wu N et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283–286PubMedCrossRef

68.

Tetsumoto S, Osa A, Kijima T et al (2011) Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. doi:10.1007/s10147-011-0256-9

69.

Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16:88–92PubMedCrossRef

70.

Ekenel M, Hormigo AM, Peak S et al (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223–227PubMedCrossRef

71.

Tham YL, Hinckley L, Teh BS et al (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRef

72.

Paydas S, Bicakci K, Yavuz S (2009) Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med 20:96–99PubMedCrossRef

73.

Rivera E, Meyers C, Groves M et al (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348–1354PubMedCrossRef

74.

Fidler IJ, Yano S, Zhang RD et al (2002) The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncol 3:53–57PubMedCrossRef

75.

Bhaskara A, Eng C (2008) Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer 7:65–68PubMedCrossRef

76.

Kim LS, Huang S, Lu W et al (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107–118PubMedCrossRef

77.

Posner JB (1996) Brain metastases: 1995 a brief review. J Neurooncol 27:287–293PubMedCrossRef

78.

Ku GY, Krol G, Ilson DH (2007) Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol 25:e14–e16PubMedCrossRef

79.

Cvetkovic RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs 66:791–820PubMedCrossRef

80.

Marcus R, Hagenbeek A (2007) The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl 67:5–14PubMedCrossRef

81.

Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350–1355PubMedCrossRef

82.

Chamberlain MC, Johnston SK, Van Horn A et al (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91:271–277PubMedCrossRef

83.

Bernstein SH, Unger JM, Leblanc M et al (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the southwest oncology group. J Clin Oncol 27:114–119PubMedCrossRef

84.

Canales M, Peñarrubia MJ, Salar A et al. (2008) Efficacy and safety of intrathecal liposomal cytarabine injection given prophylactically in patients with high-risk diffuse large B-cell lymphoma: a report of 24 patients in Spain. Abstract Presented at: the 13th Congress of the European Hematology Association, Copenhagen, Denmark, 12–15 June

85.

Lim HY, Thiel E, Glantz MJ (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodkin’s lymphoma. Curr Opin Oncol 20:495–501PubMedCrossRef

Title: Novel approaches to treating leptomeningeal metastases
Authors: Jai Grewal
Marlon Garzo Saria
Santosh Kesari
Publication date: 01-01-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0686-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Novel approaches to treating leptomeningeal metastases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

A clinicopathological study of diagnostically challenging meningioma mimics

HESRG: a novel biomarker for intracranial germinoma and embryonal carcinoma

Oligodendrogliomas in children

Imaging 18F-fluorodeoxy glucose/11C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema

Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient